SEC Comment Letter for Atara Biotherapeutics, (ATRA) — Mar 20, 2026
Atara Biotherapeutics, Inc.
Date: March 20, 2026 · CIK: 0001604464 · Accession: 0000000000-26-002840
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-294377
Letter
Re: Atara Biotherapeutics, Inc. Registration Statement on Form S-3 Filed March 17, 2026 File No. 333-294377 Dear AnhCo Thieu Nguyen:
March 20, 2026
AnhCo Thieu Nguyen President and Chief Executive Officer Atara Biotherapeutics, Inc. 1280 Rancho Conejo Blvd. Thousand Oaks, CA 91320
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Daniel Crawford at 202-551-7767 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Carlton Fleming, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> March 20, 2026 AnhCo Thieu Nguyen President and Chief Executive Officer Atara Biotherapeutics, Inc. 1280 Rancho Conejo Blvd. Thousand Oaks, CA 91320 Re: Atara Biotherapeutics, Inc. Registration Statement on Form S-3 Filed March 17, 2026 File No. 333-294377 Dear AnhCo Thieu Nguyen: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Daniel Crawford at 202-551-7767 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Carlton Fleming, Esq. </TEXT> </DOCUMENT>